The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies....
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate....
Evelo Biosciences' shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial for its next-generation drug, EDP2939. A resounding ...
Evelo Biosciences Inc. EVLO, -6.73% said Tuesday it's reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The...
- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -...
Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in psoriasis. The event is binary and can make or break the company. Prior failure of EVLO's platform i...
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement – Restructured and reduced secured debt with Hor...
Restructures and reduce s secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors...
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving...